Refractory Glaucoma Management | PristynCare

Risk Factors

Patients most likely to develop refractory glaucoma include those with:

• Neovascular glaucoma from uncontrolled diabetes or retinal vein occlusion
• Prior multiple glaucoma surgeries with conjunctival scarring
• Uveitic glaucoma with chronic inflammation and synechia formation
• Aphakic glaucoma after cataract surgery in children
• Silicone oil-related glaucoma after complex vitreoretinal surgery
• Young patients with aggressive glaucoma and poor surgical healing

Who Needs This

Patients who have failed two or more glaucoma surgeries and remain with uncontrolled IOP, persistent optic nerve damage, and visual field progression are candidates for advanced refractory glaucoma management. In some cases with very advanced disease and minimal vision, the goal shifts to pain relief and globe preservation rather than visual recovery.

Diagnosis

Assessment of refractory glaucoma involves:

• Serial IOP measurement with multiple readings on maximum medication
• Visual field testing to document rate of progression
• OCT RNFL and ganglion cell complex analysis for structural damage
• Gonioscopy to assess the angle and synechiae
• Assessment of previous surgical history (bleb morphology, tube position)
• Evaluation of the second eye for comparison and risk assessment

Treatment Plan

The treatment approach for refractory glaucoma is individualized. For eyes with reasonable visual function, additional surgical options including a second tube shunt, MIGS, or cyclophotocoagulation are explored. For eyes with minimal vision and severe pain, palliative cyclodestruction (TSCPC) or retrobulbar alcohol injection may be used to control pain. Enucleation is considered only in blind, painful eyes as a last resort.

Cyclophotocoagulation Steps

Transscleral cyclophotocoagulation (TSCPC) for refractory glaucoma involves:

• Anesthesia: periorbital injection of local anesthetic or general anesthesia
• A G-probe is placed on the conjunctival surface over the ciliary body
• Laser energy (810 nm diode laser) is delivered through the sclera to the ciliary body
• Approximately 16 to 20 applications are made at 1.5 mm posterior to the limbus
• The inferior 180 degrees is treated first; superior 180 degrees treated if needed
• Post-procedure anti-inflammatory and IOP-lowering drops are applied
• IOP response is assessed at 4 to 6 weeks; repeat treatment may be needed
• ECP (endoscopic cyclophotocoagulation) may be used simultaneously during intraocular surgery

Recovery After Treatment

Recovery after cyclophotocoagulation or advanced glaucoma surgery includes:

• Significant post-procedure inflammation is common; treated with steroid drops
• IOP may fluctuate in the first 4 to 8 weeks before stabilizing
• Glaucoma drops are continued until IOP response is confirmed
• Pain is managed with systemic analgesics in the first 48 hours
• Follow-up at 1 week, 4 weeks, and 3 months post-procedure
• Repeat cyclophotocoagulation may be needed if IOP remains elevated

Risks and Complications of Refractory Glaucoma Surgery

Complications associated with refractory glaucoma treatments include:

• Hypotony: Excessively low IOP after cyclodestruction causing vision loss
• Phthisis bulbi: Atrophy and shrinkage of the eye after excessive cyclodestruction
• Persistent inflammation: Prolonged uveitis after cyclophotocoagulation
• Vision loss: Risk of further visual field or light perception loss after aggressive treatment
• Pain recurrence: IOP may rise again requiring repeat procedures
• Sympathetic ophthalmia: Rare inflammatory response in the fellow eye after multiple intraocular procedures